Ultragenyx Pharmaceutical stock has had a difficult long term run, with the share price down about 74.4% over the past 5 years, yet current valuation checks still suggest investors are not getting a clear bargain. Recent gains have come alongside important product news, which makes the current pricing worth a closer look rather than a simple reaction to headlines.

• The roughly 74.4% decline over 5 years points to a company that has already seen a major reset in investor expectations. This can leave remaining shareholders focused on execution risk and capital needs.
• The recent accelerated FDA approval for Genglycos as Ultragenyx’s first gene therapy can support long term growth expectations. The risk is that the company may still face uncertainty around uptake, pricing and the cost of building out its rare disease portfolio.
• The broader valuation checks give a mixed picture rather than a clear bargain or clear overvaluation for Ultragenyx, with a value score of 4 that sits in the middle of the range.

The issue now is whether Ultragenyx’s current share price fairly reflects the balance between its newly approved therapy, its long track record of share price declines, and the still mixed valuation signals.

Scan beyond Ultragenyx Pharmaceutical and compare how other rare disease and quality-focused stocks are priced by running the hand-picked 46 high quality undervalued stocks for potential opportunities on your watchlist.

Has Ultragenyx Pharmaceutical Run Too Far on Sales?

P/S is often a useful way to compare Ultragenyx Pharmaceutical with other biotechs because many companies in the sector still report losses and do not have a meaningful P/E ratio.

Ultragenyx trades on a P/S of about 3.6x, which is below the wider biotech industry average of 12.9x and also below the peer group average of 6.6x. On the surface that suggests the market is applying a discount to each dollar of Ultragenyx revenue compared with many other biotechs.

The fair P/S ratio for Ultragenyx is estimated at 2.6x based on its size, risk profile and financial characteristics. That is lower than the current 3.6x level, which suggests the stock may be overvalued on this framework even though it trades at a discount to the broader industry. Despite the recent approval of Genglycos and any impact that may have on sentiment, the current P/S still reflects a higher valuation than the fair ratio estimate.

On this preferred P/S multiple framework, Ultragenyx Pharmaceutical stock currently appears overvalued relative to its estimated fair ratio benchmark.

The Ultragenyx Pharmaceutical Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Ultragenyx Pharmaceutical pick up where the P/S discussion leaves off and set out what would need to happen to Ultragenyx Pharmaceutical's growth, margins and earnings for today’s price to look meaningfully high or low. Each one links its number to a clear view of where the company’s growth, profitability and risks could go next, which you can revisit as new information and results come through, and they are available on the Community page.

Community views on Ultragenyx Pharmaceutical sit far apart, with one camp focused on upside from gene therapies and another on structural cash burn.

Bull case: 72% undervalued

"The company's highly scalable manufacturing infrastructure and increasing operational discipline are positioning Ultragenyx to capture winner-takes-most economics in select rare disease verticals…"

Bear case: roughly fairly valued

"Ultragenyx has phenomenal science, but its commercial execution is a cash-incinerating treadmill."

Do you think there's more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying!

The Bottom Line

Ultragenyx Pharmaceutical screens as overvalued on the preferred P/S framework, even though it trades at a discount to many biotech peers. That mix suggests the stock is neither a clear bargain nor an obvious outlier and puts more weight on execution than on simple relative pricing. For you as an investor, the key question is whether Ultragenyx can convert its rare disease pipeline into sustained, commercially efficient revenue without stretching its valuation further. The central issue in the bull versus bear debate is whether potential gene therapy demand and operating discipline justify paying above the estimated fair sales multiple today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.